AnalystsRyan DeschnerRyan Deschner's Stock Forecasts
AnalystsRyan Deschner
Sectors:
Industries:
Analyst Ranking
Top 30%
#1431 out of 4870 analysts
Average Return
+16.01%
Win Rate
80%8 out of 10
Risk vs Reward
Poor
Good
Ryan Deschner's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Trevi Therapeutics IncTRVI | +118.35% | $3.16 | $6.90 | 2024-08-29 - 2025-05-01 | Buy |
Liquidia CorpLQDA | +42.80% | $9.79 | $13.98 | 2024-08-18 - 2025-05-01 | Strong Buy |
Ars Pharmaceuticals IncSPRY | +26.54% | $11.19 | $14.16 | 2024-07-24 - 2025-05-01 | Buy |
Ars Pharmaceuticals IncSPRY | +24.65% | $11.36 | $14.16 | 2025-01-13 - 2025-05-01 | Strong Buy |
Trevi Therapeutics IncTRVI | +13.67% | $6.07 | $6.90 | 2025-03-09 - 2025-05-01 | Strong Buy |
Ryan Deschner Analyst Color
Get additional color on Ryan Deschner's coverage of popular stocks
Ryan Deschner's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Inozyme Pharma IncINZY | 1 | Buy | $12.00 | +891.74% | Maintains | 2 months ago |
Trevi Therapeutics IncTRVI | 2 | Strong Buy | $29.00 | +320.29% | Upgrades | 2 months ago |
Ardelyx IncARDX | 1 | Strong Buy | $13.00 | +137.66% | Reiterates | 2 months ago |
Ars Pharmaceuticals IncSPRY | 3 | Strong Buy | $28.00 | +97.74% | Maintains | 4 months ago |
Liquidia CorpLQDA | 2 | Strong Buy | $27.00 | +93.13% | Upgrades | 8 months ago |
Omega Therapeutics IncOMGAQ | 1 | Buy | $12.00 | +8,291.61% | Initiates Coverage On | 10 months ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.